Apogee Therapeutics, Inc. 8-K

What Happened

• On March 23, 2026, Apogee Therapeutics (APGE) announced positive 52‑week maintenance results from Part A of its randomized, placebo‑controlled Phase 2 APEX trial of zumilokibart (APG777) in patients with moderate‑to‑severe atopic dermatitis (AD). The company released a press release and data presentation and held a conference call the same day.
• The 52‑week maintenance evaluation tested 360 mg zumilokibart given at 3‑month and 6‑month dosing intervals. Results showed durable responses at Week 52 among Week‑16 responders and deepening efficacy across the full treated population for lesion and itch endpoints. Key safety findings: 71.4% experienced any treatment‑emergent adverse event (TEAE), serious TEAEs were 0.8%, and discontinuations for TEAEs were 3.4%.

Key Details

• EASI‑75 (maintenance among Week‑16 responders): 75% (every 3 months) and 85% (every 6 months). Overall EASI‑75 (all treated patients): 88% (3‑month) and 81% (6‑month).
• vIGA 0/1 (maintenance among Week‑16 responders): 86% (3‑month) and 78% (6‑month); overall vIGA 0/1: 72% (3‑month) and 52% (6‑month).
• Itch NRS reduction among Week‑16 responders: 77% (3‑month) and 67% (6‑month); overall itch reduction: 73% (3‑month) and 64% (6‑month).
• EASI‑90 overall: 75% (3‑month) vs. 48% (6‑month); EASI‑100 overall: 41% (3‑month) vs. 19% (6‑month). Most common TEAEs ≥5%: noninfective conjunctivitis (13.4%), URTI (12.6%), nasopharyngitis (9.2%), dermatitis atopic (5.0%).

Why It Matters

• Durable, deepening efficacy at 52 weeks with infrequent maintenance dosing (every 3 or 6 months) could be a competitive advantage if confirmed in larger trials, because less frequent dosing is attractive to patients and payors. Safety was generally consistent with the IL‑13/AD class based on the reported TEAE profile.
• Near‑term clinical catalysts listed by the company: APEX Part B 16‑week induction data expected Q2 2026, potential initiation of Phase 3 in 2H 2026 (subject to outcomes), and a possible commercial launch in 2029 if trials and regulatory paths succeed. These upcoming readouts are the next material milestones investors will watch.